The Short Version
The Dietary Supplement Health and Education Act of 1994 — DSHEA — created a distinct legal framework for dietary supplements, which FDA generally regulates as a category of food rather than as drugs.
Most dietary supplements do not undergo FDA premarket approval for safety or effectiveness. Some products containing a new dietary ingredient require a premarket safety notification to FDA — which is not the same as FDA approval.
Most new prescription drugs must undergo FDA review and approval before marketing, based on evidence of safety and effectiveness for their intended use.
Supplements may make several regulated types of claims. The most common are structure/function claims describing support for normal body structure or function. A supplement cannot lawfully be marketed to diagnose, treat, cure, mitigate, or prevent a disease unless it satisfies the separate rules that apply to drugs or permitted disease-risk-reduction health claims.
The familiar FDA disclaimer is required when a label makes a structure/function claim or certain related claims — not on every supplement bottle.
Independent, product-specific certification from USP, NSF, or ConsumerLab can provide evidence about product quality, but it does not prove that a supplement will improve a specific health condition.
A Bit of History
On October 25, 1994, President Bill Clinton signed the Dietary Supplement Health and Education Act into law as Public Law 103-417. DSHEA amended the Federal Food, Drug, and Cosmetic Act and created a distinct statutory framework for dietary supplements in the United States (NIH Office of Dietary Supplements).
The law emerged during a period of significant debate about federal oversight of vitamins, minerals, herbs, and other nutritional products. The resulting statute generally treats dietary supplements as a category of food rather than as drugs. Drugs ordinarily require FDA review and approval before they can be marketed for a particular medical use. Dietary supplements generally do not. Instead, the manufacturer bears the responsibility for making sure its product is safe, properly manufactured, accurately labeled, and not marketed with unlawful claims (FDA: Questions and Answers on Dietary Supplements).
The statutory definition of a dietary supplement is broad: it can contain a vitamin, mineral, herb or botanical, amino acid, dietary substance used to supplement the diet, or a concentrate, metabolite, constituent, extract, or combination of these ingredients — everything from vitamin D3 and magnesium to probiotics, fish oil, and multi-ingredient blends (NIH ODS, DSHEA text).
Congress found in 1994 that approximately 600 US supplement manufacturers produced about 4,000 products. Today’s marketplace is vastly larger, though there is no authoritative government count of every supplement currently for sale. Industry sources estimated US supplement sales at approximately $69.3 billion in 2024 — an industry estimate rather than an audited government total (Nutrition Business Journal estimate, via Nutraceuticals World).
What DSHEA Actually Does
Three features of DSHEA matter most for patients and clinicians.
No routine FDA premarket approval
Unlike most new prescription drugs, dietary supplements generally do not go through a finished-product FDA approval process before they reach store shelves. There is no dietary-supplement equivalent of a New Drug Application.
That does not mean supplements are unregulated — the regulatory model is simply different. Manufacturers remain responsible for ensuring that products are not adulterated or misbranded, that they are manufactured according to applicable standards, and that label claims are truthful and not misleading. FDA may inspect facilities, monitor the marketplace, review labeling, issue warning letters, oversee voluntary recalls, and take other enforcement action. In limited circumstances, FDA also has mandatory-recall authority for dietary supplements when the statutory standard is met (FDA: Questions and Answers on Dietary Supplements; FDA: Questions and Answers Regarding Mandatory Food Recalls).
A different premarket pathway for new ingredients
Some supplements do require a premarket FDA notification. A New Dietary Ingredient, or NDI, is generally an ingredient that was not marketed in a US dietary supplement before October 15, 1994. A manufacturer intending to market a supplement containing an NDI generally must submit a notification to FDA at least 75 days before introducing the product into interstate commerce, unless a statutory exception applies. The notification must provide the basis for concluding that the ingredient, under the labeled conditions of use, can reasonably be expected to be safe.
This is an important safety requirement, but it is still not FDA approval. FDA may object to an inadequate notification, but the process does not involve the comprehensive premarket review required for a new prescription drug (FDA: New Dietary Ingredient Notification Process).
Manufacturers have affirmative quality obligations
It is not quite accurate to say supplement companies simply “police themselves.” Manufacturers carry the primary legal responsibility for compliance, governed by FDA rules. Companies that manufacture, package, label, or hold dietary supplements must comply with dietary-supplement current Good Manufacturing Practices (cGMPs), which are intended to ensure that a product meets specifications for identity, purity, quality, strength, and composition.
But cGMP compliance is not the same as FDA pre-approval. A product can be made in a compliant facility and still lack strong evidence that it improves a particular symptom, disease, or health outcome (FDA: Questions and Answers on Dietary Supplements).
What FDA Drug Approval Looks Like
The contrast becomes clearer when you look at the typical pathway for a new prescription drug. Not every product follows an identical pathway, but a typical new drug is first studied under an Investigational New Drug (IND) application and then evaluated through a New Drug Application (NDA) before marketing (FDA: The Drug Review Process — Ensuring Drugs Are Safe and Effective; FDA: The Drug Review Process — Continued).
The path generally includes preclinical laboratory and animal studies, an IND submission before most human trials, Phase 1 safety studies in roughly 20 to 80 participants, Phase 2 dose-finding studies in dozens to several hundred, Phase 3 effectiveness studies often involving hundreds to thousands, an NDA containing the full clinical and manufacturing package, formal FDA review, and post-marketing surveillance after approval.
Trial design, endpoints, and duration vary by disease and drug type. The key point is not that every drug study looks identical — it is that a new drug sponsor generally must provide FDA with evidence of safety and effectiveness before marketing.
A dietary supplement manufacturer generally does not conduct Phase 1, 2, or 3 clinical trials before selling a product. There is no supplement equivalent of an NDA and no routine FDA review team assigned to decide whether a finished supplement is effective before consumers can buy it. That is not a hidden loophole — it is the legal design of DSHEA.
Neither regulatory system is perfect. Drug development is expensive, slow, and cannot detect every rare or long-term safety issue before approval. The supplement system is faster and more permissive, but it does not ordinarily provide the same level of FDA premarket verification for a finished product.
What Supplement Claims Mean
One of the most useful skills a patient can develop is learning how to read the wording of a supplement claim. Supplements may make several kinds of regulated claims, and the legal category matters because each has different requirements.
Structure/function claims describe the role of a nutrient or dietary ingredient in supporting normal body structure or function — for example, “calcium builds strong bones,” “fiber helps maintain bowel regularity,” or “magnesium supports normal muscle function.” These claims do not require FDA pre-approval, but the manufacturer must have substantiation that the claim is truthful and not misleading, and must notify FDA of the claim’s text within 30 days after first marketing. Notification is not approval (FDA: Structure/Function Claims).
Health claims describe a relationship between a substance and reduced risk of a disease or health-related condition — for example, “adequate calcium intake may reduce the risk of osteoporosis.” This is a disease-risk-reduction health claim, subject to a different regulatory framework than structure/function claims. Depending on the claim, FDA authorization or carefully qualified wording may be required. It is different from saying a product treats existing osteoporosis — that would be a disease-treatment claim, generally placing the product in drug territory (Congressional Research Service Report R48623).
Disease claims are what a supplement cannot lawfully make. A product marketed to diagnose, treat, cure, mitigate, or prevent a disease may meet the legal definition of a drug because of its intended use. Language like “lowers blood pressure,” “treats atrial fibrillation,” “reverses coronary artery disease,” “prevents heart attacks,” or “cures diabetes” cannot lawfully appear on a supplement label without meeting the requirements that apply to drugs (FDA: Questions and Answers on Dietary Supplements).
A useful comparison:
ClaimLegal categoryGeneral regulatory meaning”Calcium builds strong bones.”Structure/functionMay be permissible if truthful, non-misleading, substantiated”Adequate calcium intake may reduce the risk of osteoporosis.”Health claimMay be permitted only under applicable health-claim requirements”Calcium treats osteoporosis.”Disease-treatmentGenerally a drug claim”Fiber helps maintain bowel regularity.”Structure/functionMay be permissible if properly substantiated”Fiber treats diverticulitis.”Disease-treatmentGenerally a drug claim
The familiar FDA disclaimer
When a supplement label makes a structure/function claim — or certain related claims — it must carry this disclaimer:
“This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”
The disclaimer is not required on every supplement bottle. It appears when a manufacturer uses the types of claims that trigger the DSHEA disclaimer requirement.
The key phrase is not “no one has ever looked at this.” A company may have relied on studies, published research, or scientific reviews when making its claim. What the disclaimer means is more specific: FDA has not evaluated the claim before the product was marketed. The manufacturer is still legally responsible for having substantiation that an eligible claim is truthful and not misleading, but manufacturer substantiation is not the same as FDA premarket approval — and neither is automatically equivalent to high-quality clinical proof that the supplement improves a specific disease outcome (FDA: Structure/Function Claims).
What Third-Party Certification Means
Because supplements are not routinely FDA-approved before sale, independent product certification can be helpful. But it is essential to understand what a certification mark does — and does not — mean.
The most useful distinction is this: quality verification is not clinical proof of benefit. A supplement may contain the listed ingredient, match its label claim, and meet contaminant specifications, yet still have little meaningful evidence that it improves your particular symptom, diagnosis, or long-term health outcome.
USP Verified. The US Pharmacopeial Convention operates a voluntary Dietary Supplement Verification Program for selected finished products. To earn the USP Verified Mark, a manufacturer undergoes a facility audit for compliance with applicable Good Manufacturing Practices. USP verifies that a product contains the ingredients listed on its label in the declared potency and amount, and does not contain harmful levels of specified contaminants (USP Dietary Supplement Verification Program).
NSF certification. NSF certifies dietary supplements under standards evaluating specific quality and safety criteria — whether the product’s contents match label declarations and whether certain contaminants or undeclared ingredients are present at unacceptable levels. NSF Certified for Sport is especially relevant for competitive athletes because it includes testing to reduce the risk that a product contains substances prohibited in sports (NSF Product and Ingredient Certification).
ConsumerLab. ConsumerLab independently tests supplement products and offers a voluntary Quality Certification Program. Its testing may assess ingredient identity, quantity, selected contaminants, disintegration, or other quality characteristics. Its independent reviews can identify products that do not contain expected amounts of an ingredient or do not meet applicable quality expectations (About ConsumerLab.com).
USP, NSF, and ConsumerLab use different program structures, standards, sampling methods, and reporting practices. A consumer should verify what the particular mark on a specific product represents, rather than relying on a general quality claim by the brand. And none of these seals establish that a supplement treats disease, prevents disease, or produces a particular clinical benefit.
The quality question is: “Is this product reasonably consistent with its specifications?” The clinical-evidence question is: “Does this product improve a meaningful health outcome?” Those are separate questions, and patients deserve clear answers to both.
What This Means for You
Nothing in DSHEA makes supplements inherently bad. Some are useful, some have meaningful biological effects, and some are reasonable to consider for particular nutritional deficiencies, treatment goals, or patient populations. But the legal framework matters because it tells you what has — and has not — been independently verified before a product reaches the shelf.
Practical takeaways:
Read the wording carefully. “Supports,” “helps maintain,” and “promotes” commonly signal structure/function language. “Treats,” “cures,” “prevents,” “reverses,” and “lowers disease risk” call for closer scrutiny — they may be drug claims or health claims subject to separate rules.
Understand the disclaimer. If you see the familiar FDA disclaimer, FDA has not evaluated the statement before marketing. That does not prove the claim is false, but it does tell you the product has not gone through the drug-approval process.
Look for product-specific quality verification. USP, NSF, and ConsumerLab can provide useful information about identity, quantity, manufacturing controls, and selected contaminant testing. Verify the certification applies to the exact product and formulation you are considering.
Do not confuse purity with proof. A supplement can be accurately labeled and well manufactured yet still lack convincing evidence it improves a symptom, diagnosis, or meaningful clinical outcome.
Consider the dose. Evidence, risks, and interactions often depend on the actual dose and chemical form — not simply the ingredient name on the front label.
Bring supplements to your clinician. The actual bottles, a photo of the Supplement Facts panel, or a complete list with doses. Unreported supplement use can contribute to unexpected lab findings, adverse effects, and drug–supplement interactions.
Ask three separate questions. First: is this product likely to contain what it says it contains? Second: is there good evidence this ingredient, at this dose, helps someone like me? Third: is it safe with my conditions and medications?
The practical goal is not to fear supplements or assume they are ineffective. It is to recognize the difference between FDA approval, manufacturer responsibility, quality certification, and evidence of clinical benefit. A supplement may be legally sold without FDA premarket approval, manufactured to acceptable quality specifications, and carry a substantiated structure/function claim — yet still lack convincing clinical evidence that it improves a particular disease or patient outcome.
That is the story the label is trying to tell you. Once you understand it, you are in a much stronger position to decide what belongs in your cabinet — and what is worth discussing at your next office visit.
This article is educational and does not replace individualized medical advice. Do not start, stop, or change any supplement or medication without discussing it with your clinician.
Sources
DSHEA and dietary-supplement regulation
Dietary Supplement Health and Education Act of 1994, Public Law 103-417. NIH Office of Dietary Supplements. https://ods.od.nih.gov/About/DSHEA_Wording.aspx
Questions and Answers on Dietary Supplements. US Food and Drug Administration. https://www.fda.gov/food/information-consumers-using-dietary-supplements/questions-and-answers-dietary-supplements
New Dietary Ingredient Notification Process. US Food and Drug Administration. https://www.fda.gov/food/dietary-supplements/new-dietary-ingredient-ndi-notification-process
Food and Dietary Supplement Labeling Claims: FDA Regulation and Select Legal Issues. Congressional Research Service Report R48623. https://www.congress.gov/crs-product/R48623
Claims and disclaimers
Structure/Function Claims. US Food and Drug Administration. https://www.fda.gov/food/nutrition-food-labeling-and-critical-foods/structurefunction-claims
Drug approval
The FDA’s Drug Review Process: Ensuring Drugs Are Safe and Effective. US Food and Drug Administration. https://www.fda.gov/drugs/information-consumers-and-patients-drugs/fdas-drug-review-process-ensuring-drugs-are-safe-and-effective
FDA’s Drug Review Process: Continued. US Food and Drug Administration. https://www.fda.gov/drugs/information-consumers-and-patients-drugs/fdas-drug-review-process-continued
FDA recall authority
Questions and Answers Regarding Mandatory Food Recalls. US Food and Drug Administration. https://www.fda.gov/media/117429/download
Independent quality programs
USP Dietary Supplement Verification Program. https://www.usp.org/verification-services/dietary-supplements-verification-program
NSF Product and Ingredient Certification. https://www.nsf.org/nutrition-wellness/product-and-ingredient-certification
About ConsumerLab.com. https://www.consumerlab.com/about/
Market context
The State of Supplements: US Market Approaches $70 Billion. Nutraceuticals World. https://www.nutraceuticalsworld.com/exclusives/the-state-of-supplements-u-s-market-approaches-70-billion/